Emerging research and political debates threaten to redefine HPV vaccination guidelines in the US, with some experts advocating for a single-dose schedule to improve coverage and efficacy.
Parents of preteens may soon hear a familiar recommendation framed in a new way: one dose of the HPV vaccine may eventually be enough for some children, rather than the two-dose schedule now advised in the United States. The discussion reflects how much has changed since the vaccine was introduced two decades ago, and how much of the medical debate has shifted from whether to vaccinate to how best to do it. According to NBC Chicago, federal officials and medical organisations have both been revisiting long-standing guidance, even as they remain at odds on broader immunisation policy.
HPV, or human papillomavirus, is the most common sexually transmitted infection in the United States and is linked to a wide range of cancers, including cancers of the cervix, anus, mouth and throat. The Centers for Disease Control and Prevention says HPV is responsible for nearly all cervical cancers and most anal cancers, which is why the vaccine is recommended routinely at ages 11 or 12, with the option to begin as early as 9. The National Cancer Institute says the shot is most effective before exposure to the virus and that protection lasts for more than a decade.
The public health impact has been substantial. CDC data show steep declines in infections caused by the HPV types most likely to lead to cancer and genital warts, along with a fall in cervical precancers among vaccinated women. The agency says HPV infections in teen girls have dropped sharply since vaccination programmes began, and the broader evidence base continues to grow. A Cochrane review concluded that vaccination before age 16 greatly reduces cervical cancer risk, while a study highlighted by the CDC found protection appears long-lasting.
Yet vaccination rates have levelled off. NBC Chicago reported that about 63% of teenagers have received the full two-dose series, a figure that has stayed flat for four years. The same report noted that the HPV vaccine can be harder to sell than other adolescent shots because it is known to sting more and can sometimes lead to fainting. Doctors also say questions about pain are common among families weighing whether to proceed.
The question now is whether the schedule itself should change again. The CDC currently recommends two doses for children who start the series before their 15th birthday and three doses for those who begin later or who are immunocompromised. But evidence has prompted some experts to consider whether a single dose could provide enough protection for at least some patients. Research cited by NBC Chicago included a Costa Rica study of more than 20,000 girls that found one shot offered about 97% protection against cervical cancer, and a JAMA Oncology study that found vaccinated males were nearly 50% less likely to develop several HPV-related cancers.
That debate has also become entangled in Washington’s broader battle over vaccine policy. NBC Chicago reported that Health and Human Services Secretary Robert F. Kennedy Jr., who previously worked on litigation involving Merck’s Gardasil vaccine, ordered a one-dose recommendation in January as part of a wider change to the childhood immunisation schedule, but the move was blocked by a federal judge. Medical groups, including the American Academy of Pediatrics, have been studying the evidence independently and say the key issue is not whether HPV vaccination works, but how to make it as effective and practical as possible. For now, experts still advise two shots for most children, while stressing that vaccination itself remains the main goal because it prevents cancer.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
